Modus Outcomes will present two posters on the #PRO results of two hematological cancer clinical trials conducted with GSK and Takeda at the 62nd ASH Annual Meeting and Exposition taking place on December 5-8. Register now for #ASH20: hematology.org/meetings/annua…

Best wishes for 2021 from the Modus Outcomes team! Thank you for a productive 2020. We look forward to continuing to work with you in the new year to measure what matters to patients. youtu.be/OhdAAReziF4 #HappyNewYear #PatientCenteredOutcomes #ConceptDrivenMeasurement

Interested in the use of Patient Reported Outcomes in Medical Device Evaluation? Here is Part 1 of 4 of Modus Outcomes Q&A session on our reflections of the FDA/CDRH Industry’s Virtual Public Meeting held in the Fall 2020: youtu.be/DuK_19vvV_A #PROs #MedicalDevice #MDDT

Interested in learning more about the interpretation and meaning of patient-reported outcome results? Here is Part 3 of 4 of Modus Outcomes Q&A session on our reflections of the FDA/CDRH Industry's Virtual Public Meeting held in the Fall 2020: youtube.com/watch?v=AJ-q-5… #PROs #MDDT

Interested in Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) clinical trials and patient-centered outcome measures? Please see our Spotlight On: modusoutcomes.com/spotlight-on/s… #PatientCenteredOutcomes #ClinicalTrials #Duchenne #SpinalMuscularAtrophy

At #MADID2021, Modus Outcomes will present the findings of a qualitative study, conducted in partnership with Regeneron, considering the heretofore unexplored symptoms and daily life impacts of #COVID19 on outpatients. #PatientCenteredOutcomes #QualitativeResearch

At #EHA2021, Modus Outcomes is presenting a landscape review, which includes a series of graphical displays, applied to real clinical trial data, to illustrate how #PROCTCAE data can be used to gain a better understanding of the patient experience of symptomatic toxicities.